Product description

BPC-157 and TB-500 is a research blend that brings together two peptides in one product. Both have drawn interest in studies focused on healing tissues even though their research backgrounds and the amount of evidence supporting them are not the same.

BPC-157 is a peptide made up of 15 amino acids. Has the sequence GEPPPGKPADDAGLV. The studies that have been published are mainly done before trials and have looked at things like tendon healing, tissues in the stomach blood vessel reactions, inflammation and other related body functions.

TB-500 is often called Ac-LKKTETQ, which's an acetylated fragment made of seven amino acids. This fragment comes from parts 17 to 23 of beta 4. The difference can be hard to notice. Thymosin beta 4 has 43 amino acids in total so results, from using the molecule cannot just be assumed to come from the shorter part.

Interest in combining the two developed largely because their experimental literature overlaps around tissue response and repair. Direct evidence for the blend itself was scarce for years. In 2026, researchers compared the individual peptides, their combination and a control in an Achilles tendon injury model in rats. The study provides useful data on the formulation as a research concept, but it does not establish clinical effects in humans.

Why BPC-157 & TB-500

The rationale for studying these compounds together comes from different, partly overlapping lines of preclinical research.

Earlier work with BPC‑157 looked at tendon cells and experimental tendon injuries along with models. In rats that had an Achilles tendon investigators reported changes in biomechanical measurements changes in fibroblast activity changes in collagen formation and changes in functional recovery. Those findings made people interested in BPC‑157 as a laboratory tool, for studying repair processes.

The research history behind TB-500 is less straightforward. Much of the broader literature concerns thymosin β4 rather than the short Ac-LKKTETQ fragment itself. Its actin-binding region has been investigated in connection with endothelial-cell migration, angiogenesis and wound repair. Short sequences derived from this region subsequently became research subjects in their own right.

A 2024 study helps draw that line more clearly. Researchers examined Ac-LKKTETQ and its metabolites in vitro and in rats. In a fibroblast wound-healing assay, the parent peptide did not show the significant activity sometimes inferred from thymosin β4 research. One metabolite, Ac-LKKTE, did.

That result makes simple assumptions about the blend difficult. Putting two peptides into one formulation creates an opportunity to study their combined behavior, but it does not mean their experimental effects will add together.

Research applications

Tendon repair currently offers the most direct research model for the combination.

Research published in 2026 compared the two peptides separately and in combination in an experimental Achilles tendon model. Differences were observed in biomechanical and histological measures, but the combined treatment did not outperform the individual compounds.

That is a useful finding in itself. A plausible biological rationale for putting two research peptides together is not evidence of synergy.

Separate experimental work provides additional context. BPC-157 has been studied for its possible effects on tendon structure, collagen organization and functional recovery. These were animal experiments, not human clinical trials.

Research specifically involving TB-500 remains more limited. The 2024 metabolism study tracked the parent compound in human serum, enzyme systems and rats before examining it and its metabolites in fibroblast assays. No cytotoxicity was observed under the conditions tested, while the metabolite Ac-LKKTE showed significant activity in the wound-healing assay.

There is a larger literature around thymosin β4, including studies of endothelial-cell migration, angiogenesis and dermal wound repair. It provides biological context for research into peptides derived from its active region. It should not, however, be treated as direct evidence that the shorter fragment produces all of the same effects.

For the blend, the remaining questions are fairly concrete: whether the components influence the same repair pathways, whether their responses overlap, how they behave when present together, and whether observations made with each peptide separately persist in a combined experimental system. Current evidence does not settle those questions.

Available forms

Research formulations containing these peptides may be supplied in several forms:

Lyophilized powder in vials – a common laboratory format that allows material to be reconstituted at a concentration required by an experimental protocol.
Pre-formulated liquid solutions – used where a prepared research solution is appropriate for the study design.
Nasal-spray formulations – available for experimental work involving intranasal delivery models.
Pre-filled syringe pens – self-contained format that may offer more convenient handling, controlled volume selection, and consistent dispensing during laboratory work.
Oral research formulations – less common and potentially relevant when gastrointestinal exposure, stability or the delivery route itself forms part of the experiment.

Form matters. Concentration, excipients, peptide identity, stability and the ratio between the two components can all affect what is actually being tested, so these parameters should be documented for each research material rather than inferred from the product name.

Research use only

BPC-157 & TB-500 remains an investigational research blend. Available evidence comes predominantly from laboratory and animal studies, and findings from those models cannot establish efficacy in humans.

The published research does not establish a clinically validated indication, human dosing regimen or treatment protocol for the combination. Human safety data are also insufficient. Experimental findings should therefore be interpreted within the limits of the models in which they were obtained.

This material is intended strictly for laboratory research and analytical purposes. It is not intended for human or veterinary use, diagnosis, treatment, prevention or cure of disease.

Scientific sources

Biçer O et al. Jt Dis Relat Surg. 2026 – BPC-157, TB-500 and their combination in experimental Achilles tendon healing. Joint Diseases and Related Surgery
Staresinic M et al. J Orthop Res. 2003 – BPC-157 in experimental tendon healing and tendocyte research. Wiley Online Library
Rahaman KA et al. J Chromatogr B. 2024 – TB-500 metabolism, metabolites and fibroblast wound-healing assays. ScienceDirect
U.S. Food and Drug Administration. PCAC Meeting Materials. 2026 – regulatory review of BPC-157- and TB-500-related substances. FDA

BPC-157 + TB-500 Blend